Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy.
Decroos A, Meddour S, Demoy M, Piccirilli N, Rousselot P, Nicolini FE, Ragot S, Gombert JM, Herbelin A, Barbarin A, Cayssials E. Decroos A, et al. Among authors: cayssials e. Front Immunol. 2024 Nov 15;15:1473139. doi: 10.3389/fimmu.2024.1473139. eCollection 2024. Front Immunol. 2024. PMID: 39620210 Free PMC article.
Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis.
Luque Paz D, Gagelmann N, Benajiba L, Riou J, Salit RB, Orvain C, Schroeder T, Bories C, Gurnari C, Badbaran A, Boyer-Perrard F, Pagliuca S, Rautenberg C, Tavitian S, Panagiota V, Ianotto JC, Thol FR, Cayssials E, Heuser M, Rubio MT, Cassinat B, Daltro de Oliveira R, Sauter CS, Maciejewski JP, Reinhardt HC, Scott BL, Ugo V, Kröger N, Kiladjian JJ, Robin M. Luque Paz D, et al. Among authors: cayssials e. Blood Adv. 2024 Nov 19:bloodadvances.2024014368. doi: 10.1182/bloodadvances.2024014368. Online ahead of print. Blood Adv. 2024. PMID: 39561372
Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.
Huguet F, Guerci-Bresler A, Roth-Guepin G, Cayssials E, Slama B, Santagostino A, Penot A, Quittet P, Cony-Makhoul P, Saad A, Bastie JN, Hacini M, Coiteux V, Uzunov M, Roy L, Le Clech L, Berger M, Agneray AM, Messas E, Etienne G, Turhan A, Nicolini FE, Rousselot P. Huguet F, et al. Among authors: cayssials e. Br J Haematol. 2024 Dec;205(6):2295-2304. doi: 10.1111/bjh.19819. Epub 2024 Nov 6. Br J Haematol. 2024. PMID: 39506529 Free PMC article.
CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM.
Aubin L, Vilas Boas R, Daltro De Oliveira R, Le Brun V, Divoux M, Rey J, Mansier O, Ianotto JC, Pastoret C, Desmares A, Murati A, de Mas V, Tavitian S, Girodon F, Soret Dulphy J, Maslah N, Goncalves Monteiro V, Boyer F, Orvain C, Ranta D, Cayssials É, Le Clech L, Nicol C, Rottier C, Botin Lopez T, Castel B, Rispal P, Beziat G, Bescond C, Laribi K, Benajiba L, Ugo V, Lippert E, Cottin L, Luque Paz D. Aubin L, et al. Among authors: cayssials e. Am J Hematol. 2024 May;99(5):1001-1004. doi: 10.1002/ajh.27265. Epub 2024 Feb 25. Am J Hematol. 2024. PMID: 38404143
[Optimizing the use of bosutinib in patients with chronic-phase chronic myeloid leukemia: Recommendations of a panel of experts from the Fi-LMC (French CML working group)].
Rea D, Cayssials E, Charbonnier A, Coiteux V, Etienne G, Goldwirt L, Guerci-Bresler A, Huguet F, Legros L, Roy L, Nicolini FE. Rea D, et al. Among authors: cayssials e. Bull Cancer. 2024 Jan;111(1):87-96. doi: 10.1016/j.bulcan.2023.10.010. Epub 2023 Dec 11. Bull Cancer. 2024. PMID: 38087729 Free article. Review. French.
Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis.
Boucher L, Sorel N, Desterke C, Chollet M, Rozalska L, Gallego Hernanz MP, Cayssials E, Raimbault A, Bennaceur-Griscelli A, Turhan AG, Chomel JC. Boucher L, et al. Among authors: cayssials e. Int J Mol Sci. 2023 Oct 22;24(20):15441. doi: 10.3390/ijms242015441. Int J Mol Sci. 2023. PMID: 37895120 Free PMC article.
Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia.
Huguet F, Réa D, Cayssials E, Etienne G, Nicolini FE. Huguet F, et al. Among authors: cayssials e. Expert Rev Hematol. 2023 Jul-Dec;16(9):633-639. doi: 10.1080/17474086.2023.2234084. Epub 2023 Jul 27. Expert Rev Hematol. 2023. PMID: 37427999 Clinical Trial.
Germline JAK2 E846D Substitution as the Cause of Erythrocytosis?
Maaziz N, Garrec C, Airaud F, Bobée V, Contentin N, Cayssials E, Rimbert A, Aral B, Bézieau S, Gardie B, Girodon F. Maaziz N, et al. Among authors: cayssials e. Genes (Basel). 2023 May 11;14(5):1066. doi: 10.3390/genes14051066. Genes (Basel). 2023. PMID: 37239426 Free PMC article.
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
Balsat M, Alcazer V, Etienne G, Huguet F, Berger M, Cayssials E, Charbonnier A, Escoffre-Barbe M, Johnson-Ansah H, Legros L, Roy L, Delmer A, Ianotto JC, Orvain C, Larosa F, Meunier M, Amé S, Andreoli A, Cony-Makhoul P, Morisset S, Tigaud I, Rea D, Nicolini FE. Balsat M, et al. Among authors: cayssials e. Leuk Res. 2023 Jul;130:107308. doi: 10.1016/j.leukres.2023.107308. Epub 2023 May 9. Leuk Res. 2023. PMID: 37230027
39 results